N/A N=79 Cystic Fibrosis Related Bone Disease: the Role of CFTR
Cystic Fibrosis Related Bone Disease
Primary: Bone Microarchitecture and Strength Measures of the Radius and Tibia — 44.6; 40.1; 43.7 mgHA/cm3 — p=0.77
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=64 Cystic Fibrosis and Endothelial Function: At Rest and During Exercise
Cystic Fibrosis
Primary: Percentage Flow-Mediated Dilation (FMD) — 5.64; 5.32; 6.29; 7.21 percentage of change in FMD
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
N/A N=29 Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Phase 2 N=26 Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis
Vitamin D Deficiency
Primary: Safety of a Single High-dose of Oral Cholecalciferol to Treat a Vitamin D Deficiency in Children With Cystic Fibrosis — 9.57; 9.47 mg/dL
Phase 1 N=10 Clearance of 25-hydroxyvitamin D in Cystic Fibrosis
Cystic Fibrosis
Primary: Metabolic Clearance of D6-25(OH)D3 — 397; 342 mL/day
N/A N=30 Improving Vitamin D Status In Cystic Fibrosis
Cystic Fibrosis
Primary: 25-hydroxyvitamin D — 21.2; 24.4; 28.2 ng/mL
Phase 3 N=238 Study of Ataluren (PTC124™) in Cystic Fibrosis
Cystic Fibrosis
Primary: Percentage of Predicted Function (Percent-Predicted) of Forced Expiratory Volume in One Second (FEV1) at Baseline — 62.092; 60.232 percentage of predicted FEV1 — p=0.3264
N/A N=10 Effects of Mycophenolate Mofetil in Cystic Fibrosis Lung Transplant Patients
Cystic Fibrosis · Lung Transplant
Primary: Steady-state Pharmacokinetics of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Stable Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Recipients…
Phase 4 N=11 Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis
Cystic Fibrosis
Primary: Peak Plasma Concentration (Cmax) — 2.22; 2.92 mg/liter
Phase 2 N=146 28 Day Repeat Dose in Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 46; 32; 32; 2 Participants
N/A N=47 Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Weight Percentile at 3 Months — 33.5; 31.0 Weight Percentile, sex and age adjusted
N/A N=21 FDG-PET Imaging in Young Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Kinetic Influx Constant (Ki) — 0.009; 0.013 mL/min/mL
N/A N=26 Effect of Chronic Incretin-based Therapy in Cystic Fibrosis
Cystic Fibrosis · Pancreatic Insufficiency
Primary: Change in Second-phase Insulin Response Derived From the Glucose-potentiated Arginine Test as a Measure of β-cell Sensitivity to Glucose at Baseline and at 6 Months…
N/A N=21 Absorptive Clearance in the Cystic Fibrosis Airway
Cystic Fibrosis
Primary: Absorptive Clearance Rate — 42; 32 percentage of DTPA absoprtion per hour
Phase 2 N=8 Study of the Effect of VX-770 on Hyperpolarized Helium-3 Magnetic Resonance Imaging in Subjects With Cystic Fibrosis and the G551D Mutation
Cystic Fibrosis
Primary: Part A: Change From Baseline in Total Ventilation Defect Defined by Hyperpolarized Helium 3 Magnetic Resonance Imaging (3He-MRI) at Day 43 — -8.20 percentage of total…
Phase 3 N=191 Extension Study of Ataluren (PTC124) in Cystic Fibrosis
Cystic Fibrosis
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 100; 97.9; 14.7; 18.8 percent of participants
Phase 2 N=85 Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis
Cystic Fibrosis
Primary: Number of Participants With Treatment Emergent Adverse Events. — 14; 13; 15; 21 Participants
N/A N=130 Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
N/A N=10 Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Sweat Chloride Concentration — NA mmol/L
N/A N=402 Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants
Phase 2 N=21 Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis
Cystic Fibrosis
Primary: Cardiorespiratory Fitness Assessment- Modified Shuttle Walk Test Result — -6.67; -7.63 change shuttles (1 shuttle is 10 meters)
Phase 2 N=36 Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease
Cystic Fibrosis
Primary: Change in Sputum Elastase Activity — -57 micrograms/mL
N/A N=7 Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis
Cystic Fibrosis · Allergic Bronchopulmonary Aspergillosis
Primary: Number of Participants With Aspergillus Induced IL-13 Responses in CD4+ T-cells — 7 Participants
Phase 1 N=20 Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis
Cystic Fibrosis
Primary: Absorptive Clearance Rate After Isotonic Saline Inhalation — 32.0 percent cleared / 80 minutes
Phase 2 N=29 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
Cystic Fibrosis
Primary: Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1 — 62.4; 136; 338 nanograms per milliliter (ng/mL)
N/A N=22 Clinical Effects of Exercise Program Added to Pulmonary Rehabilitation in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Exercise Tolerance — 817; 792.22 meters
Phase 4 N=21 Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
Cystic Fibrosis · Cystic Fibrosis Pulmonary Exacerbation · Pseudomonas Aeruginosa Infection
Primary: Ceftolozane Clearance — 4.76 Liters per hour
Phase 2 N=60 Aerosolized Hypertonic Xylitol Versus Hypertonic Saline in Cystic Fibrosis (CF) Subjects
Cystic Fibrosis
Primary: Change in FEV1 Percentage Predicted From Baseline — 11.8; 8.8 percentage of predicted
Phase 2 N=304 Comparison of Two Treatment Regimens to Reduce PA Infection in Children With Cystic Fibrosis
Cystic Fibrosis · Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization — 24; 26; 29; 21 number of participants — p=0.86